Selected article for: "early stage and International license"
Author: Jun Fei; Lin Fu; Ying Li; Hui-Xian Xiang; Ying Xiang; Meng-Die Li; Fang-Fang Liu; De-xiang Xu; Hui Zhao
Title: Reduction of lymphocyte at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study
  • Document date: 2020_4_6
    • ID: 8q1veo3q_41
    Snippet: Several reports demonstrated that lymphocyte reduction was more obvious in critical ill patients (16) (17) (18) (19) . However, the relationship between lymphocyte reduction at the early stage and the severity and death risk of COVID-19 patients has not yet to be determined. Our results showed that the severity of COVID-19 patients was positively associated with lymphocyte reduction on admission. Moreover, fatality rate was higher in patients wit.....
    Document: Several reports demonstrated that lymphocyte reduction was more obvious in critical ill patients (16) (17) (18) (19) . However, the relationship between lymphocyte reduction at the early stage and the severity and death risk of COVID-19 patients has not yet to be determined. Our results showed that the severity of COVID-19 patients was positively associated with lymphocyte reduction on admission. Moreover, fatality rate was higher in patients with lymphocyte reduction than those of patients with normal lymphocyte. These results indicate that lymphocyte reduction elevates the severity . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • admission lymphocyte reduction and death severity: 1, 2
    • admission lymphocyte reduction and death severity risk: 1, 2
    • admission lymphocyte reduction and early stage: 1, 2, 3
    • admission lymphocyte reduction and fatality rate: 1, 2, 3
    • admission lymphocyte reduction and International license: 1, 2
    • admission lymphocyte reduction and lymphocyte reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • admission lymphocyte reduction and normal lymphocyte: 1, 2, 3, 4, 5
    • cc NC ND International license and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • cc NC ND International license and fatality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and lymphocyte reduction: 1, 2, 3, 4, 5
    • cc NC ND International license and normal lymphocyte: 1, 2, 3, 4
    • cc NC ND International license and patient severity: 1
    • critical ill patient and ill patient: 1, 2, 3, 4, 5, 6
    • death severity and early stage: 1, 2, 3, 4, 5
    • death severity and lymphocyte reduction: 1, 2
    • death severity and normal lymphocyte: 1
    • death severity and patient death severity risk: 1
    • death severity and patient severity: 1, 2, 3, 4, 5, 6